Tuhura Biosciences Inc (HURA)

$2.42 +0.02 (0.83%)
Market Cap 152.84M
Revenue (ttm) 0.00
Net Income (ttm) -30.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 446,300
Avg Vol 1,020,828
Day's Range N/A - N/A
Shares Out 63.68M
Stochastic %K 69%
Beta -0.01
Analysts Strong Sell
Price Target $8.17

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
PastaSlobCFA
PastaSlobCFA May. 12 at 1:53 AM
$HURA prelim data from the phase 1b/2a IFx-2.0 + Keytruda Study in MCC of Unknown Primary
0 · Reply
Tdc238
Tdc238 May. 11 at 11:09 PM
$HURA ifx is in skin cancer trials due to ease of administration. Deep seated tumors might require more skill and better imaging, which is why there are only two trial sites. If it works for deep seated tumors, there is no apparent reason why it would not work on any/every type of solid tumor. If I got that right, any data at esmo in oct could be a big deal. Yet it gets little mention.
1 · Reply
TuHURA_IR
TuHURA_IR May. 8 at 1:37 PM
$HURA At the core of our strategy is a clear objective: expanding the number of patients who can benefit from immunotherapy. Current checkpoint inhibitors only work in a subset of patients, largely due to resistance mechanisms within the tumor microenvironment. Our programs are designed to address those barriers directly. From Phase 3 development in Merkel Cell Carcinoma to early clinical work in AML and emerging ADC strategies, we are advancing a platform aimed at improving response rates across settings with high unmet need. We will continue to move this work forward and share progress as it develops.
0 · Reply
TuHURA_IR
TuHURA_IR May. 6 at 5:32 PM
$HURA In clinical-stage biotech, short-term price action and long-term value creation often move on different timelines. Our current focus is on advancing through defined milestones: Phase 3 enrollment for IFx-2.0, upcoming regulatory engagement for TBS-2025, and continued progress across our ADC platform. These are the drivers that shape future inflection points, particularly as data and regulatory clarity develop over time. We remain focused on execution and on building toward those milestones, which we believe are the foundation for long-term value.
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx May. 6 at 3:09 PM
$HURA here we gooooo
0 · Reply
TuHURA_IR
TuHURA_IR May. 5 at 4:46 PM
$HURA Our pipeline is built to address immunotherapy resistance from different angles. IFx-2.0 is designed to overcome primary resistance in solid tumors and is now in Phase 3. TBS-2025 focuses on acquired resistance through the VISTA pathway and is moving through early clinical development in AML. Our ADC platform adds another layer by targeting immune suppression at the myeloid level. This multi-program structure reduces dependence on a single outcome and creates multiple paths to clinical validation over time. We continue advancing each program with a focus on generating meaningful milestones across the pipeline.
0 · Reply
WhenInDoubtZoomOut
WhenInDoubtZoomOut May. 4 at 5:24 PM
$HURA when is the next data expected for Tuhura ?
1 · Reply
TrumpXTrades
TrumpXTrades May. 4 at 10:49 AM
$HURA $50 million credit facility in April 2026.Major Individual Stakeholder: Vijay Patel is consistently cited as a top shareholder, with reports indicating ownership of roughly 12% to 17% of shares outstanding. VPatel don’t dump on us, lol 🙏 Institutional Owners: Key institutional investors include Vanguard Group Inc, BlackRock, Inc., and Geode Capital Management, Llc 9+
0 · Reply
AdityaP
AdityaP May. 4 at 1:37 AM
$HURA $10 in one year .. mark this ..
0 · Reply
TuHURA_IR
TuHURA_IR Apr. 30 at 1:48 PM
$HURA Extending our anticipated cash runway into 2028 is not just about balance sheet strength. It allows us to move forward without interruption across a critical phase of development. We are continuing Phase 3 enrollment for IFx-2.0 under a defined regulatory pathway, while advancing TBS-2025 through early clinical development and progressing our ADC platform toward key proof-of-concept work. This matters because execution at this stage depends on consistency over time, not isolated updates. With funding aligned to our timeline, we are positioned to stay focused on advancing programs through the milestones that define long-term value. Follow along as we progress.
1 · Reply
Latest News on HURA
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026, 7:30 AM EDT - 1 day ago

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TuHURA Biosciences initiated with an Outperform at Citizens

2026-04-27T08:45:56.000Z - 16 days ago

TuHURA Biosciences initiated with an Outperform at Citizens

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

Apr 22, 2026, 7:30 AM EDT - 21 days ago

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

2026-04-15T12:20:48.000Z - 4 weeks ago

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

Apr 7, 2026, 7:45 AM EDT - 5 weeks ago

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Apr 1, 2026, 7:45 AM EDT - 6 weeks ago

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Mar 23, 2026, 7:45 AM EDT - 7 weeks ago

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 27, 2026, 7:30 AM EST - 2 months ago

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

Feb 24, 2026, 5:20 PM EST - 2 months ago

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers

2026-02-17T12:50:50.000Z - 3 months ago

TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

Feb 17, 2026, 7:45 AM EST - 3 months ago

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 12, 2026, 7:45 AM EST - 3 months ago

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

TuHURA Biosciences says FDA grants Orphan Drug Designation to IFx-2.0

2026-02-02T12:50:49.000Z - 3 months ago

TuHURA Biosciences says FDA grants Orphan Drug Designation to IFx-2.0

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

Feb 2, 2026, 7:45 AM EST - 3 months ago

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

2026-01-09T11:16:01.000Z - 4 months ago

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

TuHURA Biosciences announces release of Kintara’s CVR

2025-12-15T13:06:01.000Z - 5 months ago

TuHURA Biosciences announces release of Kintara’s CVR

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Dec 15, 2025, 7:50 AM EST - 5 months ago

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

TuHURA Biosciences provides updates across portfolio

2025-12-11T12:35:31.000Z - 5 months ago

TuHURA Biosciences provides updates across portfolio

TuHURA Biosciences Provides Corporate Update Following Recent Financing

Dec 11, 2025, 7:30 AM EST - 5 months ago

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences announces $15.6M registered direct offering

2025-12-09T14:55:32.000Z - 5 months ago

TuHURA Biosciences announces $15.6M registered direct offering

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

Dec 9, 2025, 9:49 AM EST - 5 months ago

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences presents research on potential role of DOR at ASH

2025-12-08T12:55:12.000Z - 5 months ago

TuHURA Biosciences presents research on potential role of DOR at ASH

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

Dec 8, 2025, 7:50 AM EST - 5 months ago

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences price target lowered to $8 from $15 at Maxim

2025-11-14T17:20:32.000Z - 6 months ago

TuHURA Biosciences price target lowered to $8 from $15 at Maxim

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 14, 2025, 7:00 AM EST - 6 months ago

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences files $250M mixed securities shelf

2025-11-03T22:35:14.000Z - 6 months ago

TuHURA Biosciences files $250M mixed securities shelf

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 6 months ago

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 9 months ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 4:15 PM EDT - 9 months ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

2025-08-12T20:40:47.000Z - 9 months ago

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 10, 2025, 4:00 AM EDT - 10 months ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

2025-07-01T12:55:33.000Z - 11 months ago

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jul 1, 2025, 8:50 AM EDT - 11 months ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 11 months ago

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

2025-06-24T12:05:10.000Z - 11 months ago

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 24, 2025, 8:00 AM EDT - 11 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

2025-06-23T21:05:17.000Z - 11 months ago

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 23, 2025, 5:00 PM EDT - 11 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TuHURA Biosciences initiated with a Buy at Brookline

2025-06-23T17:48:27.000Z - 11 months ago

TuHURA Biosciences initiated with a Buy at Brookline

TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0

2025-06-09T12:16:29.000Z - 1 year ago

TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 9, 2025, 8:00 AM EDT - 1 year ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 3, 2025, 9:58 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

Jun 2, 2025, 8:03 AM EDT - 1 year ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 15, 2025, 4:10 PM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

May 5, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 7, 2025, 8:24 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 9:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

Dec 20, 2024, 10:18 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Dec 12, 2024, 8:45 AM EST - 1 year ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Nov 25, 2024, 8:35 AM EST - 1 year ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 23, 2024, 8:30 AM EDT - 1 year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 22, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 17, 2024, 4:35 PM EDT - 1 year ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 12:54 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 16, 2024, 11:58 AM EDT - 1 year ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

PastaSlobCFA
PastaSlobCFA May. 12 at 1:53 AM
$HURA prelim data from the phase 1b/2a IFx-2.0 + Keytruda Study in MCC of Unknown Primary
0 · Reply
Tdc238
Tdc238 May. 11 at 11:09 PM
$HURA ifx is in skin cancer trials due to ease of administration. Deep seated tumors might require more skill and better imaging, which is why there are only two trial sites. If it works for deep seated tumors, there is no apparent reason why it would not work on any/every type of solid tumor. If I got that right, any data at esmo in oct could be a big deal. Yet it gets little mention.
1 · Reply
TuHURA_IR
TuHURA_IR May. 8 at 1:37 PM
$HURA At the core of our strategy is a clear objective: expanding the number of patients who can benefit from immunotherapy. Current checkpoint inhibitors only work in a subset of patients, largely due to resistance mechanisms within the tumor microenvironment. Our programs are designed to address those barriers directly. From Phase 3 development in Merkel Cell Carcinoma to early clinical work in AML and emerging ADC strategies, we are advancing a platform aimed at improving response rates across settings with high unmet need. We will continue to move this work forward and share progress as it develops.
0 · Reply
TuHURA_IR
TuHURA_IR May. 6 at 5:32 PM
$HURA In clinical-stage biotech, short-term price action and long-term value creation often move on different timelines. Our current focus is on advancing through defined milestones: Phase 3 enrollment for IFx-2.0, upcoming regulatory engagement for TBS-2025, and continued progress across our ADC platform. These are the drivers that shape future inflection points, particularly as data and regulatory clarity develop over time. We remain focused on execution and on building toward those milestones, which we believe are the foundation for long-term value.
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx May. 6 at 3:09 PM
$HURA here we gooooo
0 · Reply
TuHURA_IR
TuHURA_IR May. 5 at 4:46 PM
$HURA Our pipeline is built to address immunotherapy resistance from different angles. IFx-2.0 is designed to overcome primary resistance in solid tumors and is now in Phase 3. TBS-2025 focuses on acquired resistance through the VISTA pathway and is moving through early clinical development in AML. Our ADC platform adds another layer by targeting immune suppression at the myeloid level. This multi-program structure reduces dependence on a single outcome and creates multiple paths to clinical validation over time. We continue advancing each program with a focus on generating meaningful milestones across the pipeline.
0 · Reply
WhenInDoubtZoomOut
WhenInDoubtZoomOut May. 4 at 5:24 PM
$HURA when is the next data expected for Tuhura ?
1 · Reply
TrumpXTrades
TrumpXTrades May. 4 at 10:49 AM
$HURA $50 million credit facility in April 2026.Major Individual Stakeholder: Vijay Patel is consistently cited as a top shareholder, with reports indicating ownership of roughly 12% to 17% of shares outstanding. VPatel don’t dump on us, lol 🙏 Institutional Owners: Key institutional investors include Vanguard Group Inc, BlackRock, Inc., and Geode Capital Management, Llc 9+
0 · Reply
AdityaP
AdityaP May. 4 at 1:37 AM
$HURA $10 in one year .. mark this ..
0 · Reply
TuHURA_IR
TuHURA_IR Apr. 30 at 1:48 PM
$HURA Extending our anticipated cash runway into 2028 is not just about balance sheet strength. It allows us to move forward without interruption across a critical phase of development. We are continuing Phase 3 enrollment for IFx-2.0 under a defined regulatory pathway, while advancing TBS-2025 through early clinical development and progressing our ADC platform toward key proof-of-concept work. This matters because execution at this stage depends on consistency over time, not isolated updates. With funding aligned to our timeline, we are positioned to stay focused on advancing programs through the milestones that define long-term value. Follow along as we progress.
1 · Reply
Pcbrenna
Pcbrenna Apr. 29 at 6:25 PM
$HURA
0 · Reply
TuHURA_IR
TuHURA_IR Apr. 28 at 3:03 PM
$HURA We have secured a $50M credit facility alongside a royalty agreement designed to support the continued advancement of our pipeline and extend our anticipated cash runway into 2028. This non-equity financing structure allows us to fund ongoing clinical development, including our Phase 3 IFx-2.0 trial and the progression of TBS-2025 toward key milestones, while limiting immediate dilution for shareholders. Importantly, the facility provides flexibility, with the ability to draw capital as needed to align with operational and clinical priorities. With this in place, we are positioned to advance through critical milestones with greater financial visibility.
0 · Reply
2TrustHim
2TrustHim Apr. 27 at 7:40 PM
$HURA AI Overview As of April 27, 2026, Citizens (specifically analyst Silvan Turkcan) initiated coverage on TuHURA Biosciences, Inc. (HURA) with a "Market Outperform" rating and a price target of $9.00. MarketBeat MarketBeat +1 Key details regarding this target: Upside Potential: The $9.00 target represents a significant upside, with some reports noting it implies a roughly 282.98% increase from the price at the time of the report. Methodology: Citizens derived this target using a discounted cash flow model. Context: The initiation highlights HURA's potential to benefit from upcoming value inflection points, including preliminary results from the Phase 1b/2a trial of its personalized cancer vaccine, IFx-2.0.
0 · Reply
2TrustHim
2TrustHim Apr. 27 at 7:22 PM
$HURA https://finance.yahoo.com/markets/stocks/articles/tuhura-biosciences-hura-one-unstoppable-141438196.html
1 · Reply
michpetr
michpetr Apr. 27 at 2:20 PM
$HURA... ooohhh nooooo .. another PR saying nothing... another drop... I guess they short it too;-)
0 · Reply
TuHURA_IR
TuHURA_IR Apr. 27 at 2:13 PM
$HURA As we move through 2026, we are advancing across a sequence of planned milestones. These include continued Phase 3 enrollment for IFx 2.0, expected regulatory engagement for TBS 2025, and progression toward clinical studies in hematologic cancers. In parallel, we are advancing our ADC platform, with lead candidate selection and proof of concept studies expected in the second half of the year. We are also working toward potential Orphan Drug Designation for IFx 2.0, which could provide additional regulatory and commercial advantages. Recent third-party coverage has reflected a similar view, highlighting the breadth of the pipeline, the defined regulatory pathway for IFx 2.0, and the sequencing of clinical milestones expected throughout 2026. We believe this alignment between execution and external assessment supports a clearer understanding of the strategy currently in place.
0 · Reply
2TrustHim
2TrustHim Apr. 27 at 1:51 PM
$HURA Price Target of $9
1 · Reply
Emergency123
Emergency123 Apr. 25 at 8:31 AM
$HURA Chart looks juicy , whats a good buy in? Just picked up a load of CNBX after the laws changed. 🚀CNBX – Deep Value Biotech Flying Under the Radar 🚀 CNBX is one of those ultra-low market cap biotech plays that could move FAST when attention comes in. 💊 Cancer-Focused Pipeline CNBX is developing multiple cannabinoid-based cancer therapies, including treatments targeting colorectal, breast, prostate, and melanoma cancers. Their lead candidates like Cannabics SR and RCC-33 are aimed at massive global markets. () Got eyes on it?
0 · Reply
TuHURA_IR
TuHURA_IR Apr. 24 at 1:44 PM
$HURA We have expanded our pipeline with the addition of TBS-2025 through the acquisition of Kineta, introducing a Phase 1b-ready VISTA-inhibiting monoclonal antibody. This program is designed to target acquired resistance to immunotherapy, particularly in cancers where immune suppression driven by myeloid cells limits treatment response. In AML, this represents a setting with high unmet need and limited immunotherapy options. Beyond its standalone potential, TBS-2025 also opens the door to combination strategies and future integration with our ADC platform, increasing its strategic value. As we advance toward clinical studies, this program adds another meaningful opportunity within our pipeline.
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Apr. 24 at 10:56 AM
$HURA
0 · Reply
JacksonHole
JacksonHole Apr. 24 at 1:25 AM
$HURA tough hold. No idea what this trash will do day to day
0 · Reply
2TrustHim
2TrustHim Apr. 23 at 5:55 PM
$HURA Who is buying this dip?
0 · Reply